LEXINGTON, Mass. – Wearable sensor developer MC10 and life sciences company LabCorp have partnered to incorporate MC10’s BioStampRC health data capture system into LabCorp’s Covance Drug Development business in clinical trials and research studies. As part of the deal, LabCorp has also made an equity investment in MC10. “Our collaboration with LabCorp will accelerate the delivery of MC10’s innovative digital health solutions to our shared customer base in the pharmaceutical industry,” said Ben Schlatka, co-founder and senior vice president of corporate development at MC10, in a statement. “We are optimistic for the growing portfolio of projects that will leverage LabCorp’s differentiated diagnostic expertise and MC10’s medical-grade wearable systems to advance our mission of reshaping health care with digital solutions.” The BioStamp sensor allows for continuous, medical-grade, mobile monitoring of physiological data. To launch the collaboration, Covance is supporting the adoption of the BioStamp system in research studies best suited for the mobile monitoring of participating subjects.